SEC Form 4 · accession 0001209191-15-061133

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 15, 2015

Accepted (ET)

Jul 16, 2015 · 3:04 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 15, 2015	M	1,800	$17.16	A	347,084	D
Common Stock	Jul 15, 2015	M	10,400	$35.64	A	357,484	D
Common Stock^F2,F3	Jul 15, 2015	S	500	$131.77	D	356,984	D
Common Stock^F3,F4	Jul 15, 2015	S	2,900	$133.43	D	354,084	D
Common Stock^F3,F5	Jul 15, 2015	S	8,200	$134.23	D	345,884	D
Common Stock^F3,F6	Jul 15, 2015	S	600	$135.14	D	345,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$17.16	Jul 15, 2015	M	1,800	D	—	Jul 19, 2015	Common Stock	1,800	0	D
Stock Option (right to buy)^F7	$35.64	Jul 15, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	292,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $131.77 (range $131.20 to $132.15).
F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $133.43 (range $132.91 to $133.88).
F5Open market sales reported on this line occurred at a weighted average price of $134.23 (range $133.91 to $134.87).
F6Open market sales reported on this line occurred at a weighted average price of $135.14 (range $135.00 to $135.28).
F7Fully vested.